4 reports

  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • KTE-C19 CAR ( KITE PHARMA, INC. - PIPELINE )

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Aduro BioTech, Inc.
  • Idera Pharmaceuticals, Inc.
  • ADURO BIOTECH INC - OPPORTUNITIES
  • ADURO BIOTECH INC, MAJOR PRODUCTS AND SERVICES

Summary Aduro BioTech Inc (Aduro BioTech) is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators;...

  • Biotech
  • Cancer
  • United States
  • Company Financials
  • Aduro BioTech, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.